140 related articles for article (PubMed ID: 18827732)
1. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema.
Haller JA; Dugel P; Weinberg DV; Chou C; Whitcup SM
Retina; 2009 Jan; 29(1):46-51. PubMed ID: 18827732
[TBL] [Abstract][Full Text] [Related]
2. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome.
Williams GA; Haller JA; Kuppermann BD; Blumenkranz MS; Weinberg DV; Chou C; Whitcup SM;
Am J Ophthalmol; 2009 Jun; 147(6):1048-54, 1054.e1-2. PubMed ID: 19268890
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.
Kuppermann BD; Blumenkranz MS; Haller JA; Williams GA; Weinberg DV; Chou C; Whitcup SM;
Arch Ophthalmol; 2007 Mar; 125(3):309-17. PubMed ID: 17353400
[TBL] [Abstract][Full Text] [Related]
4. Correlation of visual acuity and macular thickness measured by optical coherence tomography in patients with persistent macular edema.
Blumenkranz MS; Haller JA; Kuppermann BD; Williams GA; Ip M; Davis M; Weinberg DV; Chou C; Whitcup SM
Retina; 2010; 30(7):1090-4. PubMed ID: 20616686
[TBL] [Abstract][Full Text] [Related]
5. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema.
Kim JE; Pollack JS; Miller DG; Mittra RA; Spaide RF;
Retina; 2008 May; 28(5):735-40. PubMed ID: 18463518
[TBL] [Abstract][Full Text] [Related]
6. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema.
Taylor SR; Habot-Wilner Z; Pacheco P; Lightman SL
Ophthalmology; 2009 Apr; 116(4):797-801. PubMed ID: 19344827
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of a dexamethasone anterior segment drug delivery system in patients after phacoemulsification.
Wadood AC; Armbrecht AM; Aspinall PA; Dhillon B
J Cataract Refract Surg; 2004 Apr; 30(4):761-8. PubMed ID: 15093636
[TBL] [Abstract][Full Text] [Related]
8. Anatomic and functional outcome after 23-gauge vitrectomy, peeling, and intravitreal triamcinolone for idiopathic macular epiretinal membrane.
Konstantinidis L; Berguiga M; Beknazar E; Wolfensberger TJ
Retina; 2009 Sep; 29(8):1119-27. PubMed ID: 19734764
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study.
Roesel M; Gutfleisch M; Heinz C; Heimes B; Zurek-Imhoff B; Heiligenhaus A
Ophthalmic Res; 2009; 42(2):81-6. PubMed ID: 19478546
[TBL] [Abstract][Full Text] [Related]
10. Pars plana vitrectomy with internal limiting membrane peeling compared with intravitreal triamcinolone injection in the treatment of diabetic macular edema.
Kim YM; Chung EJ; Byeon SH; Lee SC; Kwon OW; Koh HJ
Ophthalmologica; 2009; 223(1):17-23. PubMed ID: 18849632
[TBL] [Abstract][Full Text] [Related]
11. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema.
Gillies MC; Simpson JM; Gaston C; Hunt G; Ali H; Zhu M; Sutter F
Ophthalmology; 2009 Nov; 116(11):2182-7. PubMed ID: 19796823
[TBL] [Abstract][Full Text] [Related]
12. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers.
Holland EJ; Bartlett JD; Paterno MR; Usner DW; Comstock TL
Cornea; 2008 Jan; 27(1):50-5. PubMed ID: 18245967
[TBL] [Abstract][Full Text] [Related]
13. Posterior juxtascleral infusion of modified triamcinolone acetonide formulation for refractory diabetic macular edema: one-year follow-up.
Veritti D; Lanzetta P; Perissin L; Bandello F
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2391-7. PubMed ID: 19117937
[TBL] [Abstract][Full Text] [Related]
14. Dexamethasone intravitreal implant during phacoemulsification.
Agarwal A; Gupta V; Ram J; Gupta A
Ophthalmology; 2013 Jan; 120(1):211, 211.e1-5. PubMed ID: 23283186
[No Abstract] [Full Text] [Related]
15. Comparison between intravitreal and orbital floor triamcinolone acetonide after phacoemulsification in patients with endogenous uveitis.
Roesel M; Tappeiner C; Heinz C; Koch JM; Heiligenhaus A
Am J Ophthalmol; 2009 Mar; 147(3):406-12. PubMed ID: 19054496
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone: intravitreal implant.
Prescrire Int; 2011; 20(118):178-9. PubMed ID: 21751750
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for refractory uveitis-related macular edema.
Acharya NR; Hong KC; Lee SM
Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone-netilmicin: a new ophthalmic steroid-antibiotic combination. Efficacy and safety after cataract surgery.
Russo S; Papa V; Di Bella A; Favero A; Radulescu C; Gafencu O; Carstocea B; Milazzo G
Eye (Lond); 2007 Jan; 21(1):58-64. PubMed ID: 16273088
[TBL] [Abstract][Full Text] [Related]
19. Release and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed camera.
Meyer CH; Klein A; Alten F; Liu Z; Stanzel BV; Helb HM; Brinkmann CK
Retina; 2012; 32(10):2133-40. PubMed ID: 23060033
[TBL] [Abstract][Full Text] [Related]
20. Lamellar macular holes: tomographic features and surgical outcome.
Androudi S; Stangos A; Brazitikos PD
Am J Ophthalmol; 2009 Sep; 148(3):420-6. PubMed ID: 19493523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
